OraSure Technologies Opens NASDAQ Stock Market in Honor of World AIDS Day; Cities Across the U.S. Launch Rapid Oral Fluid HIV Testing with OraQuick ADVANCE Business Wire
click here to return to Business Wire main menu
DonateNow





OraSure Technologies Opens NASDAQ Stock Market in Honor of World AIDS Day; Cities Across the U.S. Launch Rapid Oral Fluid HIV Testing with OraQuick ADVANCE

Business Wire - December 1, 2004


BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today opened The NASDAQ Stock Market in recognition of World AIDS Day, commemorated annually on December 1. OraSure President and CEO, Douglas A. Michels, presided over The NASDAQ Market Open ceremony this morning in New York City.

This year's World AIDS Day is dedicated to women and girls. Nearly half of the estimated 37.2 million adults living with HIV worldwide are women. Millions of young women become sexually active each day with little or no access to prevention services.

"We are honored and proud to open The NASDAQ Stock Market on such an important date," said Douglas A. Michels, President and CEO of OraSure Technologies. "In order to help control HIV/AIDS and provide treatment to those in need, it is critical that individuals who may be infected learn their HIV status. OraQuick(R) ADVANCE is the only FDA-approved, CLIA-waived rapid HIV test available that can be used with oral fluid and screen for both HIV-1 and HIV-2. We believe it is the most versatile and comprehensive rapid HIV test available and are committed to making the test available to the widest possible range of customers in the United States and abroad."

The OraQuick(R) ADVANCE Rapid HIV-1/2 Antibody Test, manufactured and sold by OraSure Technologies, is the first and only U.S. Food and Drug Administration ("FDA") approved and CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood and plasma specimens.

In recognition of World AIDS Day, major cities across the United States are launching rapid oral fluid HIV testing initiatives with OraQuick(R) ADVANCE in conjunction with World AIDS Day activities.

NASDAQ Open and OraSure Interview Footage and B-Roll Available December 1

A satellite uplink with World AIDS Day and OraQuick(R) ADVANCE interview footage and b-roll are available via satellite today, Wednesday, December 1 at 2:00 - 2:15 PM EST. Coordinates for the satellite uplink are:

Date: 12-01-04

Time: 2:00 PM - 2:15 PM EST

Satellite:

KU Band - Analog

SBS6 Transponder 18 lower

74 degrees West

Downlink Frequency: 12152 Vertical

Audio: 6.2 and 6.8 full program mix

World AIDS Day footage will include: statements from NASDAQ Stock Market Opening Ceremony; b-roll of OraQuick(R) ADVANCE HIV Test procedure with oral fluid and fingerstick whole blood; additional scenes including HIV counseling; and test manufacturing. To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV-1. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

CONTACT: OraSure Technologies, Inc.

Investor Contact:

Ronald H. Spair, 610-882-1820

Investorinfo@orasure.com

www.orasure.com

or

Media Contact:

Zer0 to 5ive

Ron Ticho, 610-360-0205

rticho@orasure.com

or

Jennifer Moritz, 917-748-4006

jmoritz@0to5.com

SOURCE: OraSure Technologies, Inc.


041201
BW041203


Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .